Portland, ME, April 21, 2026 – Ovation.io, a leading provider of paired multi-omic data solutions, today announced a key milestone in building one of the fastest-growing and most comprehensive GLP-1 datasets, with the completion of 10,000 whole genome sequenced patients. The dataset includes rich, linked phenotypic data and is available for immediate licensing, providing a valuable resource for precision medicine research. The cohort is expected to grow to 25,000 patients total and include 5,000 patients with proteomic profiles.

Understand Your Competitors Performance on Genomic Subpopulations

• Current GLP-1 therapies include semaglutide, tirzepatide, liraglutide, dulaglutide, and exenatide
• Clinical data enables comparison of treatment switches and captures new to market therapies

Explore Large, Diverse Clinical and Racial Patient Populations Not Found Elsewhere

• Determine unique signatures for the 52% of underrepresented minorities, including 20.8% African ancestry and 8.5% Asian ancestry patients
• Power label expansion by understanding treatment effects and differential genomic signatures across common comorbidities including CKD, NASH/NAFLD, Neuro, Sleep Apnea and many others

Customized for Your Research Needs

• Combine with your existing data: Analysis-ready dataset delivered via Illumina Connected Analytics (ICA) with ability for data egress, or through your platform of choice
• Opportunity to quickly further enrich dataset for non-GLP-1RA exposed patients in cardiometabolic therapeutic areas (e.g. obesity, type 2 diabetes, and chronic kidney disease, liver disease)

“The development of this dataset is a major milestone for both Ovation and its clients. This effort demonstrates the ability of our sample acquisition, genomics and data teams to scale and standardize real world longitudinal data sets at unprecedented scale and speed,” said Curt Medeiros, CEO of Ovation.io. “With 10,000 patients available now for immediate licensing, this dataset is well positioned to play a meaningful role in advancing precision medicine in metabolic diseases.”

Using these data, Ovation’s collaboration with PrecisionLife has demonstrated that distinct biological signatures underlie BMI vs HbA1c responses to GLP-1. Further, these genetic and mechanistic profiles are quantifiable and independent drivers of drug response, and these responses also overlap. The analysis also suggests response markers that could shape the personalization and risk assessment of future comorbidities of other diseases, such as type 2 diabetes. This could impact both prevention and treatment approaches. Additionally, this provides a mechanistic foundation for more precise prescribing and drug-specific stratification as the GLP-1 class and reveals which subpopulations in new indications are most likely to be responsive to GLP-1s.

Ovation.io’s GLP-1 data set is available for direct delivery to clients or through partner research platforms. Ovation.io invites academic institutions, pharmaceutical companies, and clinical researchers to leverage this resource for innovative research. For more information, click here.